ReviewBMC gastroenterology2018
The characteristics of nivolumab-induced colitis: an evaluation of three cases and a literature review.
Review in BMC gastroenterology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 27 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
27 citing papers in PubMed, 56 citations in OpenAlex.
- Exploratory Clinical Study to Evaluate the Efficacy and Safety of Sulfasalazine for Immune Checkpoint Inhibitor (ICI)-Induced Colitis.JGH open : an open access journal of gastroenterology and hepatology · 2026Article
- Endoscopic findings of immune checkpoint inhibitor-related gastrointestinal adverse events.Clinical endoscopy · 2024Review
- Nivolumab-Induced Immune Mediated Colitis Localized to the Distal Colon: Seven Years Into Therapy.Cureus · 2024Article
- Atezolizumab-Induced Ulcerative Colitis in Patient with Hepatocellular Carcinoma: Case Report and Literature Review.Medicina (Kaunas, Lithuania) · 2024Review
- Anti-integrin αvβ6 autoantibodies are a potential biomarker for ulcerative colitis-like immune checkpoint inhibitor-induced colitis.British journal of cancer · 2024Article
- Prevalence of Enteric Infections in Patients on Immune Checkpoint Inhibitors and Impact on Management and Outcomes.The oncologist · 2024Article
- Checkpoint Inhibitor-Induced Colitis: From Pathogenesis to Management.International journal of molecular sciences · 2023Review
- Mesalamine and cholestyramine for immune checkpoint inhibitor-mediated diarrhea and colitis.Journal of cancer research and clinical oncology · 2023Article
- Article
- Characteristics and usefulness of transabdominal ultrasonography in immune-mediated colitis.Intestinal research · 2023Article
- Immune-Related Colitis Induced by Camrelizumab: A Case Report.Journal of inflammation research · 2023Article
- Histopathologic Features of Immune-related Adverse Events in the Gastrointestinal Tract: A Case of Severe Acute Respiratory Syndrome Coronavirus 2 and Cytomegalovirus Infection in a Patient with Lung Squamous Cell Carcinoma Receiving Immune Checkpoint Inhibitors.Juntendo Iji zasshi = Juntendo medical journal · 2022Article
- Diagnosis and Management of Immune Checkpoint Inhibitor Colitis.Gastroenterology & hepatology · 2021Article
- Immune Checkpoint Inhibitor-Associated Colitis: From Mechanism to Management.Frontiers in immunology · 2021Review
- Remission of ulcerative colitis flare-up induced by nivolumab.International journal of colorectal disease · 2020Article
- Secondary causes of inflammatory bowel diseases.World journal of gastroenterology · 2020Review
- Immune checkpoint inhibitors induced colitis, stay vigilant: A case report.World journal of gastrointestinal oncology · 2020Article
- Safe Use of Nivolumab in a Patient with Epipharyngeal Carcinoma and Preexisting Ulcerative Colitis: A Histologically Proven Case Report.Internal medicine (Tokyo, Japan) · 2020Article
- Nivolumab-induced small bowel obstruction and perforation: a rare but life-threatening side effect of immunotherapy.Emergency radiology · 2020Article
- Nivolumab-Induced Concomitant Severe Upper and Lower Gastrointestinal Immune-Related Adverse Effects.ACG case reports journal · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe use of immune-checkpoint inhibitors in cancer treatment has become increasingly common, resulting in an increase in the incidence of related side effects. Diarrhoea and colitis have been previously documented as gastrointestinal tract-related side effects of immune-checkpoint inhibitors. Although PD-1/PD-L1 inhibitors produce fewer side effects than CTLA-4 inhibitors, diarrhoea and colitis continue to be reported. However, little is known about the endoscopic features associated with PD-1/PD-L1 inhibitors. In this report, we describe three cases of colitis induced by a PD-1 inhibitor nivolumab. These cases showed endoscopic findings characteristic of ulcerative colitis (UC). Treatment was in accordance with UC therapy, which resulted in beneficial outcomes. CASE PRESENTATION: Three patients with lung cancer treated with nivolumab presented with diarrhoea with (case 2) or without haematochezia (cases 1 and 3). Treatment with nivolumab was ceased and colonoscopy was performed, revealing endoscopic features similar to those of UC. These patients were diagnosed with nivolumab-induced colitis. Case 1 was treated with mesalazine, whereas cases 2 and 3 were treated with corticosteroids. Subsequently, their symptoms improved.
conclusionsNivolumab-induced colitis exhibited similar characteristics to UC. Treatment was similar to that for UC and was successful.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.